Uses of topiramate in the treatment of alcohol dependence

References

• Manwell LB, Fleming MF, Johnson K, Barry KL. Tobacco, alcohol, and drug use in a primary care sample: 90-day prevalence and associated factors.' Addict. Dis. 17,67-81 (1998).
   Google Scholar
• Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl. Med. 348,1786–1795 (2003).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Substance-related disorders. In: Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Text revision. American Psychiatric Association, Washington DC, USA 191–223 (2000).
   Google Scholar
• Johnson BA, Ait-Daoud N, Bowden CL eta]. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361,1677–1685 (2003).
   PubMed Web of Science ®Google Scholar
• ••First demonstration that topiramate is aneffective treatment for alcohol dependence based upon a proof-of-concept, randomized, double-blind, placebo-controlled trial.
   Google Scholar
• Weiss F, Porrino U. Behavioral neurobiology of alcohol addiction: recent advances and challenges. I Neurosci 22, 3332–3337 (2002).
   Google Scholar
• Ortiz J, Fitzgerald LW Charlton M eta]. Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system. Synapse 21,289–298 (1995).
   Google Scholar
• Boehm SLIT, Piercy MM, Bergstrom HC, Phillips TJ. Ventral tegmental area region governs GABAB receptor modulation of ethanol-stimulated activity in mice. Neuroscience 115,185–200 (2002).
   PubMed Web of Science ®Google Scholar
• Kohl RR, Katner JS, Chernet E, McBride WJ. Ethanol and negative feedback regulation of mesolimbic dopamine release in rats. Psychopharmacology139,79–85 (1998).
   PubMedGoogle Scholar
• Melis M, Camarini R, Ungless MA, Bonci A. Long-lasting potentiation of GABAergic synapses in dopamine neurons after a single in vivo ethanol exposure. Neurosci. 22,2074–2082 (2002).
   Google Scholar
• Dodd PR, Beckmann AM, Davidson MS, Wike PA. Glutamate-mediated transmission, alcohol, and alcoholism. Neurochem. Int. 37,509–533 (2000).
   PubMedGoogle Scholar
• Morrisett RA, Swartzwelder HS. Attenuation of hippocampal long-term potentiation by ethanol: a patch-clamp analysis of glutamatergic and GABAergic mechanisms. I Neumsci. 13,2264–2272 (1993).
   Google Scholar
• Breese CR, Freedman R, Leonard SS. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. 674,82–90 (1995).
   Google Scholar
• Raimo EB, Schuckit MA. Alcohol dependence and mood disorders. Addict. Behar/. 23,933–946 (1998).
   PubMed Web of Science ®Google Scholar
• Senay EC. Drug abuse and public health. A global perspective. Drug- Sal 6\(Suppl. 1), 1–65 (1991).
   Google Scholar
• Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41 (Suppl. 1), S3—S9 (2000). Overview of the discovery, development, and pharmacological properties of topiramate.
   Google Scholar
• White HS, Brown SD, Woodhead JH, Skeen GA, Wolf I11 I. Topiramatemodulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41\(Suppl. 1), S17—S20 (2000).
   Google Scholar
• Schiffer WK, Gerasimov MR, Marsteller DA etal Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse 42,196-198 (2001). Important demonstration that topiramate can attenuate nicotine-induced increases in midbrain dopamine levels. Since the majority of abused drugs have been shown to increase midbrain dopamine levels, this finding would suggest that topiramate might have utility in treating a wide variety of substance use-related disorders.
   Google Scholar
• Mueller TI, Stout RL, Rudden S eta]. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol. Gun. Exp. Res. 21,86–92 (1997).
   Google Scholar
• Malcolm R, Myrick H, Brady KT, Ballenger JC. Update on anticonvulsants for the treatment of alcohol withdrawal. Ain.j Addict.10 (Suppl.), 16–23 (2001).
   Google Scholar
• •Synopsis of the effects of anticonvulsants in the treatment of alcohol withdrawal. Notably, this work includes results from the testing of new anticonvulsants.
   Google Scholar
• Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiany 32, 107–109 (1999).
   PubMed Web of Science ®Google Scholar
• Schmidt K, Nolte-Zenker B, Patzer J, Bauer M, Schmidt LG, Heinz A. Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence. Phatmacopsychiatry 34,66–72 (2001).
   PubMed Web of Science ®Google Scholar
• Swift RM. Medications and alcohol craving. Alcohol Res. Health 23,207–213 (1999).
   PubMedGoogle Scholar
• Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge eating disorder with topiramate: a clinical case series. I Gun. Psychiatry61, 368–372 (2000).
   Google Scholar
• Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Gun. Pharmacokinet. 31,29–46 (1996).
   Google Scholar
• Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 41\(Suppl. 1), S61—S65 (2000).
   Google Scholar
• Rosenfeld WE, Liao S, Kramer LD eta]. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 38, 324–333 (1997).
   Google Scholar
• Sachdeo RC, Sachdeo SK, Levy RII eta]. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 43, 691–696 (2002).
   Google Scholar
• Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RIK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 37, 774–780 (1996).
   PubMed Web of Science ®Google Scholar
• Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 44, 540–549 (2003).
   PubMed Web of Science ®Google Scholar
• Doose DR, Kohl IKA, Desai-Krieger D, Natarajan J, van Kammen DR No clinically significant effect of topiramate on haloperidol plasma concentration. Poster presented at the Eumpean College of Neuropsychopharmacology London, UK (1999).
   Google Scholar
• Doose DR, Kohl IKA, Desai-Krieger D, Natarajan J, van Kammen DR No significant effect of topiramate on lithium serum concentration. Poster presented at the World Congress of Pwchiatry Hamburg, Germany (1999).
   Google Scholar
• Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 41, 968–975 (2001).
   PubMed Web of Science ®Google Scholar
• Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clin. J: Pain 19, 59–68 (2003).
   PubMed Web of Science ®Google Scholar
• Roy Chengappa KN, Levine J, Rathore D, Parepally H, Atzert R. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur fiychiatry16, 186–190 (2001).
   Google Scholar
• Bray GA, Hollander P, Klein S etal A 6- month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res.11, 722–733 (2003).
   Google Scholar
• McElroy SL, Arnold LM, Shapira NA et al Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am. Psychiatry160, 255–261 (2003).
   PubMed Web of Science ®Google Scholar
• •Important demonstration of topiramate's ability to reduce weight and binge eating behaviors. Study suggests that topiramate may be useful in treating impulse dyscontrol behaviors other than alcohol or drug dependence.
   Google Scholar
• Biton V, Edwards KR, Montouris GD etal Topiramate titration and tolerability. Ann. Pharmacother. 35, 173–179 (2001).
   PubMedGoogle Scholar
• Kuo RL, Moran ME, Kim DH, Abrahams HM, White MD, Lingeman JE. Topiramate-induced nephrolithiasis. Endourol 16, 229–231 (2002).
   PubMed Web of Science ®Google Scholar
• Ben-Zeev B, Watemberg N, Augarten A etal Oligohydrosis and hyperthermia: pilot study of a novel topiramate adverse effect. J: Child Neural 18, 254–257 (2003).
   PubMed Web of Science ®Google Scholar
• Dodson WE, Kamin M, Kraut L, Olson WH, Wu SC. Topiramate titration to response: analysis of individualized therapy study (TRAITS). Ann. Pharmacother. 37, 615–620 (2003).
   Google Scholar
• Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. Stud. Alcohol56, 423–432 (1995).
   Google Scholar
• Fawcett J, Epstein P, Fiester SJ, Elkin I, Autry JH. Clinical management-imipramine/placebo administration manual: NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol Bull. 23, 309–324 (1987).
   PubMed Web of Science ®Google Scholar
• Bohn MJ, Barton BA, Barron KE. Psychometric properties and validity of the obsessive—compulsive drinking scale. Alcohol Clin. Exp. Res. 20, 817–823 (1996).
   Google Scholar
• Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry37, 37–40 (2004).
   Google Scholar
• •Small open-label study showing that topiramate is well tolerated and might have utility in treating alcohol-dependent individuals with comorbid psychiatric disorder.
   Google Scholar
• Anton RE Pharmacologic approaches to the management of alcoholism. J: Clin. Psychiatry62\(Suppl. 20), 11–17 (2001).
   Google Scholar